Radiopharmaceutical Therapy Roundtable

On September 30, 2025, ASTRO hosted the fifth Radiopharmaceutical Therapy Roundtable in conjunction with the ASTRO Annual Meeting in San Francisco, California. ASTRO Board members Jeff Michalski, MD, MBA, FASTRO, and Doug Martin, MD, FASTRO, along with Ana Kiess, MD, PhD, chair, and Dustin Boothe, MD, vice-chair of the ASTRO RPT Committee, led the meeting with support from Roundtable members Varian and SunNuclear.

ASTRO CEO Vivek S. Kavadi, MD, MBA, FASTRO, opened the meeting by providing organizational updates, highlighting ongoing initiatives to support the integration of RPT into clinical practice, the development of educational resources, and advocacy efforts to address policy and reimbursement barriers. These initiatives include:

Collaboration – ASTRO is actively working with SNMMI and AAPM to increase collaboration in RPT. Leaders from SNMMI and ASTRO have attended RPT meetings from the other society to ensure shared information and goals.

Increase trial-ready facilities – ASTRO is starting RPT Learning Collaboratives, including one focused on engaging with RPT Clinical Trials. The interest level is already very high. ASTRO will want industry partners to be part of these groups so members can hear directly from the source.

Increase workforce – Supported by an Educational Grant from Novartis, ASTRO is initiating two Authorized User Training Centers to help interested radiation oncologists meet regulatory requirements.

Discussion topics during the meeting included:

• Practical considerations for community and academic settings
• Clinical trials and innovation
• RPT education
• Ways that ASTRO can collaborate to advance radiopharmaceutical therapy

Other industry members that attended in person and online included Bayer, Elekta, Lantheus, MIM Software, Novartis Pharmaceuticals Corporation, OncoBeta, Perspective Therapeutics, Rayzebio, Reflexion, Theragenics. Representatives from SNMMI and AAPM were also in attendance.

In early 2023, ASTRO convened RPT industry leaders and ASTRO members, including academic and community practice physicians and physician scientists, for a strategic dialogue on the future of RPT. The meeting yielded key insights and priority areas that will drive ASTRO’s activities, including the development of a Radiopharmaceutical Roundtable, allowing vendors to help shape and prioritize the strategic direction of ASTRO’s RPT activities.

The main goal of the Roundtable is to expand the dialogue between radiation oncology professionals and industry thought leaders and extend the level of engagement and honest conversation. ASTRO is eager to undertake some of the critical topics that have emerged and work together to collaboratively address these priority areas with the Roundtable members below.